Meclizine is an antihistamine that calms inner-ear dizziness and travel nausea. It reliably eases acute vertigo, with one tablet lasting much of a day, though its motion-sickness evidence is mixed. Main drawbacks are drowsiness and drying effects like dry mouth and constipation. Heavy long-term use has been linked to greater memory decline. Newer energy-shifting, organ-protective findings remain unproven in people. (Full Review)

Protocol

Vertigo

25 mg, 1–4×/day

25–100 mg/day, titrated to symptom control

Motion Sickness

25–50 mg

~1 hour before travel, repeat every 24 h

Timing

Evening-weighted

Concentrate sedative effect toward evening for chronic vertigo

Time to effect

Vertigo Relief

~2 hours

Meaningful acute vertigo relief in pooled data

Onset

~1 hour

Symptom relief begins; dose before travel

Duration

Up to 24 hours

Effect persists despite 5–6 h half-life; once-daily dosing

Benefits

High: Relief of vertigo and vestibular dizziness

Medium: Prevention and relief of motion sickness; suppression of nausea and vomiting

Speculative: Cytoprotection via metabolic preconditioning; neuroprotection through glycolytic shift; longevity-relevant mitochondrial modulation

Contraindications

Narrow-angle glaucoma

Prostate enlargement with significant urinary retention

Severe hepatic impairment (Child-Pugh Class C)

Older adults (age ≥65, Beers Criteria)

Children under 12

Pregnancy (medical guidance only)

Key Interactions

CNS depressants (benzodiazepines, opioids, barbiturates, sedating antidepressants)

Other anticholinergic drugs (tricyclics, oxybutynin, scopolamine)

OTC antihistamines and sleep aids (diphenhydramine, doxylamine)

Alcohol

CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, bupropion)

Sedating supplements (valerian, kava, melatonin, cannabidiol)

Risk & Side Effects

High: Sedation and drowsiness; anticholinergic effects

Medium: Cognitive impairment and long-term dementia-risk signal; psychomotor impairment and fall risk in older adults

Low: Paradoxical excitation and other uncommon effects

Speculative: Consequences of chronic mitochondrial respiration suppression

Monitoring

Marker	Target	Why
Cognitive screen (attention/memory)	Stable vs personal baseline	Detects early anticholinergic cognitive effects
Anticholinergic burden score	As low as possible (0–1)	Quantifies combined load from all anticholinergic drugs
Post-void residual / urinary symptoms	Normal emptying, no retention	Flags urinary retention risk
Liver function (ALT/AST)	Within normal limits	Ensures adequate metabolism in chronic use

Cadence: Check-in at 2–4 weeks of any daily use, then every 3–6 months if use continues

Qualitative Assessment

Degree and timing of drowsiness and next-day grogginess
Dry mouth, constipation, or blurred vision
Steadiness and fall near-misses, especially in older users
Whether target symptoms (vertigo, motion nausea) are controlled
Subjective mental clarity and memory over weeks of use

Meclizine for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment